HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-armed, multicentric, explorative phase II clinical research of
conversional therapy with combination of hepatic arterial infusion chemotherapy(HAIC),
Donafenib Tosilate and Toripalimab for unresectable hepatocellular carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University